CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone–proguanil against falciparum malaria in Vietnam

Summary Objectives To study a new combination, based on dihydroartemisinin and piperaquine (CV8) and atovaquone/proguanil (Malarone) for treatment of uncomplicated falciparum malaria in Vietnam. Methods Vietnamese adults with falciparum malaria were allocated randomly to treatment with dihydroartemisinin/piperaquine/trimethoprim/primaquine 256/2560/720/40 mg (CV8, n = 84) or Malarone 3000/1200 mg (n = 81), both over 3 days. Patients were followed‐up for 28 days. Results All patients recovered rapidly. The mean (95% CI) parasite elimination half‐life of CV8 was 6.8 h (6.2–7.4) and of Malarone 6.5 h (6.1–6.9) (P = 0.4). Complete parasite clearance time was 35 (31–39) and 34 h (31–38) (P = 0.9). The 28‐day cure rate was 94% and 95%, respectively (odds ratio 0.84, 95% CI 0.18–3.81). No significant side‐effects were found. Conclusion CV8 and Malarone are effective combinations against multi‐drug resistant falciparum malaria. CV8 has the advantage of a low price.